189 related articles for article (PubMed ID: 25186909)
1. Systems consequences of amplicon formation in human breast cancer.
Inaki K; Menghi F; Woo XY; Wagner JP; Jacques PÉ; Lee YF; Shreckengast PT; Soon WW; Malhotra A; Teo AS; Hillmer AM; Khng AJ; Ruan X; Ong SH; Bertrand D; Nagarajan N; Karuturi RK; Miranda AH; Liu ET
Genome Res; 2014 Oct; 24(10):1559-71. PubMed ID: 25186909
[TBL] [Abstract][Full Text] [Related]
2. A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.
Marotta M; Chen X; Inoshita A; Stephens R; Budd GT; Crowe JP; Lyons J; Kondratova A; Tubbs R; Tanaka H
Breast Cancer Res; 2012 Nov; 14(6):R150. PubMed ID: 23181561
[TBL] [Abstract][Full Text] [Related]
3. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes.
Kao J; Pollack JR
Genes Chromosomes Cancer; 2006 Aug; 45(8):761-9. PubMed ID: 16708353
[TBL] [Abstract][Full Text] [Related]
4. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.
Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V
Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995
[TBL] [Abstract][Full Text] [Related]
6. [DNA structural features on the borders of ERBB2 amplicons in breast cancer].
Matsenko NIu; Kovalenko SP
Mol Biol (Mosk); 2013; 47(5):818-27. PubMed ID: 25509354
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
[TBL] [Abstract][Full Text] [Related]
8. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers.
Tripathy D; Benz CC
Cancer Treat Res; 1992; 63():15-60. PubMed ID: 1363356
[TBL] [Abstract][Full Text] [Related]
9. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
10. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
11. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Kauraniemi P; Bärlund M; Monni O; Kallioniemi A
Cancer Res; 2001 Nov; 61(22):8235-40. PubMed ID: 11719455
[TBL] [Abstract][Full Text] [Related]
12. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
[TBL] [Abstract][Full Text] [Related]
13. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Riaz M; van Jaarsveld MT; Hollestelle A; Prager-van der Smissen WJ; Heine AA; Boersma AW; Liu J; Helmijr J; Ozturk B; Smid M; Wiemer EA; Foekens JA; Martens JW
Breast Cancer Res; 2013 Apr; 15(2):R33. PubMed ID: 23601657
[TBL] [Abstract][Full Text] [Related]
14. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer.
Kalyana-Sundaram S; Shankar S; Deroo S; Iyer MK; Palanisamy N; Chinnaiyan AM; Kumar-Sinha C
Neoplasia; 2012 Aug; 14(8):702-8. PubMed ID: 22952423
[TBL] [Abstract][Full Text] [Related]
15. Aberrations of ERBB2 and TOP2A genes in breast cancer.
Nielsen KV; Müller S; Møller S; Schønau A; Balslev E; Knoop AS; Ejlertsen B
Mol Oncol; 2010 Apr; 4(2):161-8. PubMed ID: 19945923
[TBL] [Abstract][Full Text] [Related]
16. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
17. Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer.
Vidgren V; Varis A; Kokkola A; Monni O; Puolakkainen P; Nordling S; Forozan F; Kallioniemi A; Vakkari ML; Kivilaakso E; Knuutila S
Genes Chromosomes Cancer; 1999 Jan; 24(1):24-9. PubMed ID: 9892105
[TBL] [Abstract][Full Text] [Related]
18. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
19. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.
Zito CI; Riches D; Kolmakova J; Simons J; Egholm M; Stern DF
Genes Chromosomes Cancer; 2008 Jul; 47(7):633-8. PubMed ID: 18418848
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors.
Wu G; Sinclair C; Hinson S; Ingle JN; Roche PC; Couch FJ
Cancer Res; 2001 Jul; 61(13):4951-5. PubMed ID: 11431322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
